Minocycline and Tissue-Type Plasminogen Activator for Stroke
نویسندگان
چکیده
منابع مشابه
Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.
BACKGROUND AND PURPOSE New treatment strategies for acute ischemic stroke must be evaluated in the context of effective reperfusion. Minocycline is a neuroprotective agent that inhibits proteolytic enzymes and therefore could potentially both inactivate the clot lysis effect and decrease the damaging effects of tissue-type plasminogen activator (t-PA). This study aimed to determine the effect o...
متن کاملRecombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke
THE FOOD AND DRUG ADMINIStration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials (1 and...
متن کاملTissue-type plasminogen activator for acute ischemic stroke.
BACKGROUND AND PURPOSE Several studies are currently evaluating tissue-type plasminogen activator (TPA) as a potential therapy in acute ischemic stroke. The possibility of inducing intracranial hematomas, however, introduces an important concern into ultimate evaluation of risk and benefit. This retrospective analysis sought to identify factors associated with intracranial hematoma formation in...
متن کاملThe Argatroban and Tissue-Type Plasminogen Activator Stroke Study
See related article, page 770. Developing new interventions for hyperacute stroke remains an important aim because current treatment options remain limited to alteplase, aspirin, hemicraniectomy, and stroke unit care. Over the last 20 years, drug developments have largely focused on fibrinolytic, neuroprotective, and anticoagulant strategies. Although the first is proven, the second and third r...
متن کاملTissue-plasminogen activator for acute ischaemic stroke.
BACKGROUND Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2009
ISSN: 0039-2499,1524-4628
DOI: 10.1161/strokeaha.109.556852